ADAMTS-19 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-19 (UniProt Q8TE59), HEK293-expressed. Suited for extracellular matrix protease activity assays, inhibitor profiling, and antibody validation alongside matched TPB antibody RP-ADAMTS19.
Expression system
HEK293
Cat. #
REC-ADAMTS19

In stock

SKU
REC-ADAMTS19
$498.00

Target Overview

ADAMTS-19 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 19; UniProt Q8TE59) is a secreted, multi-domain zinc metalloprotease of the ADAMTS family, comprising 1,213 amino acids. Like other family members, its domain architecture includes a prodomain, a catalytic metalloprotease domain, a disintegrin-like domain, a central thrombospondin type-1 repeat, a cysteine-rich domain, a spacer domain, and additional thrombospondin type-1 repeats in the ancillary region — structural features that position ADAMTS-19 for extracellular matrix (ECM) remodelling and pericellular proteolysis. ADAMTS-19 is annotated at EC 3.4.24.- and localises to the extracellular space and ECM upon secretion. This recombinant is produced in human HEK293 cells, providing mammalian glycosylation and folding conditions that are particularly relevant for a secreted protease whose activity and stability depend on correct post-translational processing. HEK293 expression minimises concerns about refolding artefacts common to prokaryotic systems. In the laboratory, REC-ADAMTS19 is suitable as a positive-control antigen in Western blot and immunoprecipitation experiments, as a standard for ELISA quantification, and as an enzyme source for substrate-cleavage and inhibitor-screening assays once specific substrates are identified for this family member. Researchers validating antibody specificity can pair this recombinant directly with the matched Triple Point Biologics antibody (RP-ADAMTS19), which has been validated for Western blot applications — a pairing that streamlines confirmation of band identity and epitope accessibility under denaturing and native conditions. The full-length 1,213-residue sequence context makes REC-ADAMTS19 particularly useful where multi-domain recognition or conformational epitope validation is required.

Background

ADAMTS-19 belongs to the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) protease family, a group of 19 secreted, multi-domain metalloendopeptidases that collectively regulate extracellular matrix turnover, versican processing, procollagen maturation, and a range of developmental signalling events. While several ADAMTS family members — including ADAMTS-4, -5, -13, and -1 — have well-characterised substrates and extensive biochemical literature, ADAMTS-19 remains among the less-studied members of the family, making well-characterised recombinant protein a particularly useful reagent for establishing baseline enzymatic and binding data. Genetically, ADAMTS19 has been identified through mutation screening in the context of connective tissue disorders. A 2026 review by Alcocer et al. (Physiology, Bethesda) catalogued ADAMTS and ADAMTSL mutations associated with a spectrum of connective tissue phenotypes, placing ADAMTS-19 within a broader family-level research framework that investigators are actively mapping (PMID: 41915433). This positions the recombinant as a useful tool for researchers characterising genotype–phenotype relationships at the protein function level. Beyond connective tissue biology, ADAMTS19 has appeared as a candidate locus in population-scale genomic studies of sporadic Parkinson's disease, where Eubanks et al. identified rare risk variant burden across gene expression networks (Cell Rep, 2025; PMID: 40317721). The mechanistic link between ADAMTS-19 and neurodegeneration-associated ECM changes remains an open research question, and the recombinant protein provides a starting point for in vitro functional studies aimed at addressing it. ADAMTS19 expression has also been examined as a potential prognostic marker in endometriosis-associated ovarian cancer, where transcriptomic profiling studies have flagged it among a panel of differentially expressed genes (Yang et al., Int J Med Sci, 2024; PMID: 39113897). Similarly, expression-level changes have been noted in reproductive phenotype models. These observations collectively frame ADAMTS-19 as a research target across oncology, reproductive biology, and neurological disease contexts — none of which are yet defined mechanistically, reinforcing the need for well-characterised recombinant protein to support substrate identification, interactome mapping, and inhibitor profiling studies. Triple Point Biologics has produced proteinase and inhibitor antibodies since 1994, and REC-ADAMTS19 is developed with the same attention to characterisation that underlies the matched antibody reagent (RP-ADAMTS19).

Applications

  • Antibody validation positive control — confirm band identity in Western blot when used alongside matched antibody RP-ADAMTS19
  • ELISA standard curve calibration for quantifying endogenous ADAMTS-19 in conditioned media or tissue lysates
  • Substrate cleavage profiling — incubation with candidate ECM substrates (e.g., versican, aggrecan fragments) followed by SDS-PAGE or mass spectrometry readout
  • Metalloprotease inhibitor IC50 determination using fluorogenic peptide substrate formats adapted from related ADAMTS family assays
  • Immunoprecipitation input control to confirm antibody pull-down specificity under native buffer conditions
  • Protein–protein interaction studies to identify putative binding partners or co-factors in the extracellular space
  • IHC antigen standard — use as a spike-in or section-coating control when optimising RP-ADAMTS19 for tissue staining protocols

References

  1. Alcocer AD et al. ADAMTS and ADAMTSL mutations in connective tissue disorders. Physiology (Bethesda). 2026. doi:10.1152/physiol.00043.2025. PMID: 41915433.
  2. Eubanks E et al. Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease. Cell Rep. 2025. doi:10.1016/j.celrep.2025.115636. PMID: 40317721.
  3. Amin SN et al. Comparing the Effect of Heat Therapy and Mitochondrial-Targeted Antioxidants in Polycystic Ovarian Syndrome Phenotype Induced by Junk Food Consumption. Reprod Sci. 2025. doi:10.1007/s43032-024-01755-w. PMID: 39821756.
  4. Eubanks E et al. Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease. bioRxiv. 2024. doi:10.1101/2024.08.30.610195. PMID: 39257816.
  5. Yang H et al. Identification and Validation of Prognostic Markers for Endometriosis-Associated Ovarian Cancer. Int J Med Sci. 2024. doi:10.7150/ijms.97024. PMID: 39113897.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant ADAMTS-19 on SDS-PAGE and Western blot?

ADAMTS-19 (UniProt Q8TE59) has a predicted unprocessed molecular weight of ~134 kDa based on its 1,213-amino acid sequence. The HEK293-expressed recombinant carries mammalian N- and O-linked glycosylation, so the apparent band on reducing SDS-PAGE typically migrates at 150–165 kDa — meaningfully higher than the sequence-predicted mass. If you are using RP-ADAMTS19 for Western blot, load this recombinant as your positive control and expect the band in that 150–165 kDa window, not at the theoretical unglycosylated weight.

What processing form is the recombinant ADAMTS-19 — full-length or mature active form, and is the prodomain removed?

The recombinant is produced in HEK293 cells and secreted into conditioned medium, which allows endogenous furin-like proprotein convertases in the secretory pathway to process the prodomain cotranslationally, mirroring physiological maturation. The product therefore represents the mature, prodomain-processed form retaining the catalytic metalloprotease domain, disintegrin-like domain, cysteine-rich domain, spacer domain, and ancillary thrombospondin type-1 repeats. Purity is >90% by SDS-PAGE. If your experiment requires the zymogen form, this preparation is not suitable.

What substrates can I use to measure recombinant ADAMTS-19 proteolytic activity in a fluorescence assay?

ADAMTS-19 is a zinc metalloprotease (EC 3.4.24.-) with broad ECM substrate relevance. For fluorometric activity assays, the generic metalloprotease FRET substrate Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (commonly used for ADAMTS family members) provides a practical starting point; monitor cleavage at Ex/Em 320/405 nm. Proteoglycan-derived peptides such as aggrecan IGD-region sequences are more physiologically relevant if substrate selectivity matters for your model. Include 5 mM CaCl2 in the reaction buffer — already present in the supplied storage buffer — as calcium is required for catalytic activity.

What is the recommended activity assay buffer for ADAMTS-19 recombinant protein and do I need to add zinc or calcium?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. For fluorometric or cleavage assays, dilute directly into a reaction buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35. Zinc is structurally incorporated into the metalloprotease active site and does not need to be supplemented; adding exogenous ZnCl2 above low micromolar concentrations can paradoxically inhibit activity. Keep reaction pH between 7.0–7.8 — activity drops sharply outside this range for ADAMTS family metalloproteases.

What starting concentration and dilution range should I use for recombinant ADAMTS-19 in enzyme activity dose-response experiments?

For initial activity titrations, a working range of 0.5–10 nM (roughly 0.07–1.4 µg/mL based on ~140 kDa apparent MW) covers the linear response window for most FRET-substrate assays. Start at 2 nM as a single-point screen; if signal is saturated, dilute down in the assay buffer rather than in the storage glycerol-containing buffer to avoid substrate interference. For inhibitor IC50 determinations, fix enzyme at 1–2 nM (near the Km-relevant concentration) and titrate inhibitor across 8–10 points. Always pre-incubate enzyme at 37°C for 10 min before adding substrate.

Can I use recombinant ADAMTS-19 as a positive control for Western blot with the RP-ADAMTS19 rabbit polyclonal antibody?

Yes — this is the primary validated use case for pairing REC-ADAMTS19 with RP-ADAMTS19. The matched rabbit polyclonal antibody (RP-ADAMTS19) was raised and validated in the same laboratory, and compatibility between antigen and antibody is confirmed. Load 50–100 ng of recombinant per lane on a 4–12% Bis-Tris gel under reducing conditions; expect a band at 150–165 kDa. This pairing is particularly useful when setting up ADAMTS-19 detection in tissue or cell lysates for the first time, giving you an unambiguous size reference and confirming antibody performance on your gel system.

How much recombinant ADAMTS-19 should I load as a positive control, and what antibody dilution works with RP-ADAMTS19?

Load 50–100 ng per lane for a clean positive control band with RP-ADAMTS19; going above 200 ng risks smearing given the glycoprotein heterogeneity. For the antibody, a starting dilution of 1:1,000–1:2,000 in 5% non-fat milk/TBST works for most standard ECL detection systems. If background is high, switch the blocking buffer to 5% BSA/TBST, which is generally preferable for phospho-independent targets including metalloproteases. RP-ADAMTS19 is validated for Western blot; cross-reactivity with other ADAMTS family members has not been validated, so it should not be assumed.

How should I store recombinant ADAMTS-19 and what is the shelf life after thawing?

Store at -20°C in the supplied single-use aliquots; do not refreeze after thawing. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is formulated for long-term stability, and glycerol prevents freeze-induced aggregation. Once thawed, keep on ice and use within 4–8 hours; metalloprotease activity declines with extended time at room temperature due to autoproteolysis. For experiments requiring dilution below ~0.1 µg/mL, add carrier protein (0.1% BSA) to the dilution buffer to prevent adsorptive losses to tube walls.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS19 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →